St. Jude Medical

Rank: 21
2015 Rank16
R&D Spend:$676,000,000
Fiscal year ending:01/02/16
Click here to see all 100

St. Jude Medical made a big splash just before we went to press, announcing plans to acquire cardiac assist device maker Thoratec for $3.4 billion. The company also acquired Spinal Modulation for $215 million this year, and last year closed the deal for what CEO Daniel Starks calls its most important growth driver: the CardioMEMS Champion HF implantable heart monitor.

Abbott and St. Jude Medical, Inc. announced today a definitive agreement for Abbott to acquire St. Jude Medical, creating a premier medical device leader with top positions in high-growth cardiovascular markets. St. Jude Medical received U.S. Food and Drug Administration (FDA) approval of the company’s proprietary, first-to-market MultiPoint Pacing technology.

2015 Top 500 Solar Contractors Key Personnel: Michael Rousseau, President & CEO; Daniel Starks, Chairman; John Heinmiller, EVP; Lisa Andrade, VP & Chief Marketing Advisor; Paul Bae, VP, Global HR & Chief Compliance Officer; Joel Becker, President, Americas; Dr. Mark Carlson, VP, Global Clinical Affairs & Chief Medical Officer; Jeffrey Dallager, VP & Controller; Philip Ebeling, VP, CTO; Rachel Ellingson, VP, Strategy; Dr. Eric Fain, President; Jeff Fecho, VP, Global Quality; Denis Gestin, President, International; Mark Murphy, VP, IT & CIO; Scott Thome, VP, Global Operations & Supply Chain; Jason Zellers, VP, GC & Secretary; Donald Zurbay, VP, Finance & CFO;

Saint Paul, Minnesota